SCHEMBL19974282

SCHEMBL19974282

C#Cc1cnc(NC(=O)/C=C/C(=O)O)s1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.40
KDM4E B2RXH2 5/20 0.39
ALDH1A1 P00352 5/20 0.39
GSTO1 P78417 1/20 0.39
LPAR2 Q9HBW0 3/20 0.38
LPAR3 Q9UBY5 2/20 0.38
KMT2A Q03164 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
MEN1 O00255 2/20 0.38
HTT P42858 2/20 0.38
BLM P54132 1/20 0.38
LPAR1 Q92633 1/20 0.37
TDP2 O95551 1/20 0.37
GAA P10253 1/20 0.37
THRB P10828 1/20 0.37
NMT1 P30419 1/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19974283 1.00 MAPT (0.40) MAPTKDM4EALDH1A1GSTO1LPAR2
SCHEMBL3014320 0.81 SMN1; SMN2 (0.41) KMT2ASMN1; SMN2NPC1RAB9AMEN1
SCHEMBL30271563 0.80 MAPT (0.57) MAPTKDM4EALDH1A1KMT2ASMN1; SMN2
SCHEMBL19974146 0.77 RAB9A (0.59) MAPTKDM4EALDH1A1KMT2ASMN1; SMN2
SCHEMBL19974148 0.77 RAB9A (0.59) MAPTKDM4EALDH1A1KMT2ASMN1; SMN2
SCHEMBL12851919 0.76 SMN1; SMN2 (0.36) KMT2ASMN1; SMN2NPC1RAB9AMEN1
SCHEMBL19260113 0.72 GSTO1 (0.72) MAPTKDM4EALDH1A1GSTO1LPAR2
SCHEMBL19974173 0.72 GSTO1 (0.72) MAPTKDM4EALDH1A1GSTO1LPAR2
SCHEMBL3018930 0.70 CA1 (0.44) RAB9A
SCHEMBL20929227 0.69 SMN1; SMN2 (0.36) ALDH1A1KMT2ASMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3512602-B1 INHIBITORS OF HEAT SHOCK FACTORS (HSF) AND USES THEREOF HSF PHARMACEUTICALS (CH) 2024-03-27 EP disclosed
US-11597708-B2 Inhibitors of heat shock factors and uses thereof HSF PHARMACEUTICALS SA (CH) 2023-03-07 US disclosed
US-20210221778-A1 Inhibitors of heat shock factors and uses thereof HSF PHARMACEUTICALS SA (CH) 2021-07-22 US disclosed
EP-3512602-A2 INHIBITORS OF HEAT SHOCK FACTORS AND USES THEREOF HSF Pharmaceuticals (CH) 2019-07-24 EP disclosed
WO-2018050656-A2 INHIBITORS OF HEAT SHOCK FACTORS AND USES THEREOF HSF PHARMACEUTICALS (CH) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11597708-B2 Inhibitors of heat shock factors and uses thereof HSF1, HSP90AB2P, HSP90AB1 MAPT 2930/4885KDM4E 2977/4885ALDH1A1 2641/4885
US-20210221778-A1 Inhibitors of heat shock factors and uses thereof HSF1, HSP90AB2P, HSP90AB1 MAPT 2930/4885KDM4E 2977/4885ALDH1A1 2641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.